1. Homepage
  2. Equities
  3. Hong Kong
  4. Hong Kong Stock Exchange
  5. Shanghai Junshi Biosciences Co., Ltd.
  6. News
  7. Summary
    1877   CNE100003FF7

SHANGHAI JUNSHI BIOSCIENCES CO., LTD.

(1877)
  Report
Delayed Hong Kong Stock Exchange  -  09:36 2022-06-26 pm EDT
46.80 HKD   +4.12%
06/14Shanghai Junshi Biosciences Lowers Expected Total Proceeds for Proposed Issuance
MT
06/14Shanghai Junshi Biosciences Obtains Approval for Clinical Trial of EGFR Inhibitor Tablets
MT
06/13SHANGHAI JUNSHI BIOSCIENCES CO., LTD.(SHSE : 688180) added to SSE 180 Index
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Junshi's COVID-19 Drug Candidate Shows Positive Results in Small Trial; Shares Jump Nearly 7% in Shanghai, Hong Kong

05/19/2022 | 01:00am EDT


© MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
GILEAD SCIENCES, INC. 0.80% 63.08 Delayed Quote.-13.12%
SHANGHAI JUNSHI BIOSCIENCES CO., LTD. 4.12% 46.8 Delayed Quote.-22.50%
All news about SHANGHAI JUNSHI BIOSCIENCES CO., LTD.
06/14Shanghai Junshi Biosciences Lowers Expected Total Proceeds for Proposed Issuance
MT
06/14Shanghai Junshi Biosciences Obtains Approval for Clinical Trial of EGFR Inhibitor Table..
MT
06/13SHANGHAI JUNSHI BIOSCIENCES CO., LTD : 688180) added to SSE 180 Index
CI
06/13SHANGHAI JUNSHI BIOSCIENCES CO., LTD : 688180) added to Shanghai Stock Exchange 180 Value ..
CI
06/07Shanghai Junshi Gets Chinese Regulator's Approval for Clinical Trial of Investigational..
MT
06/06Junshi Biosciences Highlights Pipeline Advances in Immuno-Oncology Through Nearly 40 Da..
GL
05/26UBS Adjusts Shanghai Junshi Biosciences' Price Target to HK$70.90 From HK$77.70, Keeps ..
MT
05/26Junshi Biosciences JV Cleared to Start Clinical Trial in China of Cancer Drug
MT
05/25Chinese Shares Rebound; Junshi Jumps 4% in Shanghai as COVID-19 Tablet Finishes Clinica..
MT
05/24VV116 Versus PAXLOVID Phase III Registrational Trial for Early Treatment of Mild to Mod..
GL
More news
Analyst Recommendations on SHANGHAI JUNSHI BIOSCIENCES CO., LTD.
More recommendations
Financials
Sales 2022 2 413 M 361 M 361 M
Net income 2022 -1 804 M -270 M -270 M
Net cash 2022 2 750 M 411 M 411 M
P/E ratio 2022 -23,7x
Yield 2022 -
Capitalization 62 749 M 9 381 M 9 381 M
EV / Sales 2022 24,9x
EV / Sales 2023 17,2x
Nbr of Employees 2 805
Free-Float 21,3%
Chart SHANGHAI JUNSHI BIOSCIENCES CO., LTD.
Duration : Period :
Shanghai Junshi Biosciences Co., Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SHANGHAI JUNSHI BIOSCIENCES CO., LTD.
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 11
Last Close Price 38,31 CNY
Average target price 52,28 CNY
Spread / Average Target 36,5%
EPS Revisions
Managers and Directors
Cong Li Co-Chief Executive Officer & Executive Director
Ning Li General Manager & Executive Director
Bao Hong Xu Financial Director
Jun Xiong Chairman
Yu Wu Chairman-Supervisory Board
Sector and Competitors